Navigation Links
New study highlights Chagas disease as a growing health and socio-economic challenge
Date:2/8/2013

WASHINGON, D.C.February 7, 2013Today, The Lancet Infectious Diseases published a new report that examines the global economic burden of Chagas disease. In the first study of its kind, researchers measured the health and economic impact of Chagas disease and found that the total economic burden of Chagas disease matches or exceeds that of many more well-known diseases such as rotavirus, Lyme disease and cervical cancer.

Chagas disease infects an estimated 10 million people worldwide, with most cases occurring in Latin America. It is a parasitic infection transmitted through an insect commonly known as the "kissing bug." Its symptoms range from acute respiratory and intestinal infections to strokes, liver and heart disease. In some cases Chagas disease can be fatal.

The poorest countries in the region are especially impacted by this neglected tropical disease (NTD) because of the insect's propensity to live in impoverished communities that lack quality housing, access to essential medicines and vector control practices. However the new study found that while the burden is considerable in Latin America, it is also significant in parts of the world not traditionally considered risk areas for Chagas disease, such as in North America and Europe.

The study estimates that the global economic cost of Chagas disease exceeds USD $7 billion annually. This cost surpasses that of rotavirus ($2 billion) and cervical cancer ($4.7 billion). Even in the United States, the economic burden of Chagas disease is comparable to the burden of much more publicized infectious diseases such as Lyme disease. According to the study, currently infected individuals will result in more future health care costs occurring in the United States (approximately $6.7 billion) than any other country.

"Lost productivity is a big part of the cost," said the study's lead author, Dr. Bruce Lee. "By just focusing on health care costs, or simple measures such as death caused by the disease, we miss a lot of the burden. We must examine the crucial impact lost productivity can have on society, businesses, governments and other key stakeholders."

Quantifying the economic burden of Chagas disease can help guide public health policy decisions, according to the study's co-author, Dr. Peter Hotez.

"We now have more evidence that Chagas disease is more than just a burden on human health in some of the poorest countries. All around the world, Chagas disease has a huge economic impact," said Dr. Hotez. "This new data should help inform policy decisions that will prioritize Chagas disease on research, policy and development agendas. This should include support for developing new vaccines for Chagas disease."

The Sabin Vaccine Institute Product Development Partnership (Sabin PDP), in collaboration with Texas Children's Hospital, Baylor College of Medicine and other PDP partners, is currently engaged in early research and development for a bivalent therapeutic vaccine for the treatment of chronic Chagas disease. If successful, it would be the first therapeutic vaccine for the treatment of this disease.

"Further studies quantifying Chagas disease-related costs on a regional or country level will help policymakers and other decision makers establish necessary control measures," added Dr. Hotez.


'/>"/>

Contact: Johanna Harvey
johanna.harvey@sabin.org
202-621-1691
Sabin Vaccine Institute
Source:Eurekalert

Related medicine news :

1. On-the-Job Stress Wont Raise Your Risk for Cancer, Study Finds
2. Collaboration and innovation win CWRU School of Medicine grant to study gastric cancer
3. UIC researchers to study how young adults use e-cigarettes, snus
4. Docs, Families May Underestimate Patients Odds After Some Strokes: Study
5. Stroke During Childhood May Raise Risk for Epilepsy, Study Says
6. Social media may prove useful in prevention of HIV, STDs, study shows
7. Students in Educational First Steps Assisted Centers Show Persistent Benefits Far Beyond Early Childhood According to University of Texas at Dallas Study
8. Study Ties Gene to Dangerous Heart Valve Deposits
9. Electrical Brain Stimulation Plus Drug Fights Depression: Study
10. Mayo Clinic-led study identifies biomarkers for early risk assessment of acute kidney injury
11. Study to test whether hearing aids can help prevent falls
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2017)... ... July 17, 2017 , ... ... and Its Treatments during Pregnancy , studies take a closer look at maternal ... a developing baby with one study showing newer medications may be safer choices. ...
(Date:7/17/2017)... Connecticut (PRWEB) , ... July 17, 2017 , ... McGraw ... Enhance Patient Care and Train Next Generation of Healthcare Clinicians , NORWALK, Connecticut ... McGraw-Hill, is continuing its legacy of investing in community health by pledging up to ...
(Date:7/17/2017)... ... July 17, 2017 , ... Altec Products, Inc., a ... Advanced Admin Training in Atlanta, Georgia. The four-day training session, which begins ... them to manage DocLink more efficiently and effectively. , Covering topics such as ...
(Date:7/17/2017)... ... July 17, 2017 , ... ... For” by the Chronicle of Higher Education for the sixth consecutive year, and ... has campuses in Pomona, California and Lebanon, Oregon, was recognized in seven categories: ...
(Date:7/17/2017)... ... July 17, 2017 , ... Dr. Teotia is honored to receive the ... in plastic and reconstructive surgery. RealSelf is the top online resource for patients who ... last year alone. Dr. Teotia has also been asked to be a Feature Medical ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... -- Bayer has awarded grants totaling more than $2 million to ... Bayer Hemophilia Awards Program (BHAP). Four U.S. clinicians and researchers ... and Uniformed Services University of the Health Sciences in ... were announced last night during a reception at the International ... Berlin, Germany . ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... CARLSBAD, Calif. , July 10, 2017  The ... in Boston, MA at the ... unequaled value and unparalleled access to global decision makers ... to draw 800+ life science leaders during two impactful ... Boston, and provides delegates with additional networking opportunities with ...
Breaking Medicine Technology: